Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1. by Isakson, Sara H et al.
UCLA
UCLA Previously Published Works
Title
Genetically engineered minipigs model the major clinical features of human 
neurofibromatosis type 1.
Permalink
https://escholarship.org/uc/item/5027943n
Journal
Communications biology, 1(1)
ISSN
2399-3642
Authors
Isakson, Sara H
Rizzardi, Anthony E
Coutts, Alexander W
et al.
Publication Date
2018
DOI
10.1038/s42003-018-0163-y
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
ARTICLE
Genetically engineered minipigs model the major
clinical features of human neurofibromatosis type 1
Sara H. Isakson1, Anthony E. Rizzardi2, Alexander W. Coutts2, Daniel F. Carlson2, Mark N. Kirstein1,3,
James Fisher3, Jeremie Vitte 4, Kyle B. Williams1, G. Elizabeth Pluhar1,5, Sonika Dahiya6,
Brigitte C. Widemann7, Eva Dombi7, Tilat Rizvi8, Nancy Ratner8, Ludwine Messiaen9,
Anat O. Stemmer-Rachamimov10, Scott C. Fahrenkrug2, David H. Gutmann11, Marco Giovannini4,
Christopher L. Moertel1,12, David A. Largaespada1,12 & Adrienne L. Watson2
Neurofibromatosis Type 1 (NF1) is a genetic disease caused by mutations in Neurofibromin 1
(NF1). NF1 patients present with a variety of clinical manifestations and are predisposed to
cancer development. Many NF1 animal models have been developed, yet none display the
spectrum of disease seen in patients and the translational impact of these models has been
limited. We describe a minipig model that exhibits clinical hallmarks of NF1, including café au
lait macules, neurofibromas, and optic pathway glioma. Spontaneous loss of heterozygosity is
observed in this model, a phenomenon also described in NF1 patients. Oral administration of
a mitogen-activated protein kinase/extracellular signal-regulated kinase inhibitor suppresses
Ras signaling. To our knowledge, this model provides an unprecedented opportunity to study
the complex biology and natural history of NF1 and could prove indispensable for develop-
ment of imaging methods, biomarkers, and evaluation of safety and efficacy of NF1-targeted
therapies.
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NF1 is a prevalent genetic disorder, occurring in one inevery 3000 children born, with over two million casesworldwide1. NF1 patients are born with mutations in one
copy of the NF1 tumor suppressor gene, a negative regulator of
the Ras signaling pathway. Over time, the remaining wild-type
allele of NF1 may be lost in a rare cell, leading to abnormal cell
growth and division in multiple body systems. For instance,
loss of heterozygosity (LOH) in the melanocyte lineage results in
cafe au lait macules (CALMs), hyperpigmented patches of skin
present in nearly all patients, and LOH in the Schwann cell
lineage leads to the development of neurofibromas1–5. NF1
patients are predisposed to other tumors, including malignant
peripheral nerve sheath tumors, optic pathway gliomas (OPGs),
astrocytomas, and juvenile myelomonocytic leukemia1,6–9. While
there has been considerable effort to develop targeted therapies
for these tumors, few treatments show clinical efficacy10–16.
In addition to tumor predisposition, NF1 patients also commonly
suffer from skeletal abnormalities, scoliosis, short stature, learning
disabilities, hypertension, and epilepsy1,17–19.
Many murine models of NF1 have been developed, yet none
fully recapitulates the disease spectrum seen in NF1 patients20,21.
The first mouse model of NF1 was a traditional germ line het-
erozygous knockout mouse, which developed some of the less
common NF1-associated tumors, however, did not develop
neurofibromas or other characteristic symptoms of NF122,23.
More complex mouse models have since been developed to
replicate the more common features of NF1. For example, the
Cre-lox system was employed to generate mice with bi-allelic loss
of Nf1 in a specific cell lineage (e.g., astrocyte, Schwann cell), and
double mutant Nf1/Tp53 mice were developed to study malignant
peripheral nerve sheath tumors and astrocytomas. While these
models have improved our understanding of NF1-associated
tumorigenesis, each has major limitations and none display the
complexity of disease observed in NF1 patients10,24–26. More
importantly, preclinical studies in mice are often not predictive of
drug efficacy in the humans27,28.
Large animal models that better approximate human physiol-
ogy and anatomy are essential to translating discoveries from
murine models into clinical therapies. In contrast to rodents,
swine (Sus scrofa) are highly similar to humans in regard to
their nervous, integumentary, and cardiovascular systems29. The
anatomical, biochemical, and cellular components of porcine
nerves are comparable to humans, making the study of NF1-
associated nerve hyperplasia and neurofibroma development
both feasible and applicable29. The porcine eye has a pigmented
iris and retinal layers with a similar thickness to humans, allowing
the use of imaging modalities to identify Lisch nodules and
study OPG pathogenesis in swine29,30. Porcine skin is similar
to humans in structure, thickness, hair follicle content, vascular
anatomy, and collagen fiber arrangement, making these animals
ideal for studying the development of CALMs and dermal
neurofibromas29,30. NF1-associated hypertension is easily mod-
eled in the pig, which has long been used as a model for human
cardiovascular disease due to their nearly identical cardiac anat-
omy and physiology29. Finally, cytochrome P450 enzymes, which
function to metabolize drugs in humans, are genetically very
similar to those in the pig, making them a valuable model for
predicting drug efficacy and toxicology in humans30.
Recent technological advances in precision gene targeting and
somatic cell nuclear transfer have given researchers the ability to
produce genetically modified swine carrying exact disease alleles
found in human patients. Genetically engineered swine as large
animal biomedical models open a vast array of new opportunities
to study disease and develop novel, safe, and effective therapies.
Here, we describe the development and characterization of an
Ossabaw minipig model of NF1. The Ossabaw minipig is derived
from a population of feral pigs on Ossabaw Island, Georgia,
United States. They have a life expectancy of up to 15 years and
reach puberty at 5–6 months, making them an ideal animal
model for studying disease features that occur in both pediatric
and adult populations. We estimate that a 6-month-old Ossabaw
minipig is equivalent to a pubescent human and each year of life
thereafter corresponds to a decade in the human. Therefore, a
1-year-old Ossabaw minipig would correspond to a 20-year-old
human and a 2-year-old Ossabaw minipig would correspond to a
30-year old human. The long lifespan of the Ossabaw minipig
allows for longitudinal and natural history studies of human
diseases. Further, the Ossabaw minipig grows to a size of 180–220
pounds, roughly the size of an adult human, making it possible to
perform advanced imaging studies on instruments designed for
humans.
We have developed an NF1 minipig that recapitulates the
diverse phenotypes seen in NF1 patients, including the develop-
ment of CALMs, neurofibromas, and OPG. NF1 minipigs exhibit
spontaneous and cell-type-specific LOH, a critical step for both
CALM and neurofibroma development in NF1 patients and a
hallmark of NF1 that has not been observed in rodent models.
We demonstrate that NF1 minipigs can be dosed orally with a
small-molecule inhibitor, currently in clinical development for
NF1, which leads to a targeted reduction in Ras signaling. This
NF1 minipig model provides a unique opportunity to study the
complex biology and natural history of NF1 and could prove
indispensable for preclinical evaluation of NF1-targeted therapies
as well as development of imaging methods and diagnostic
biomarkers.
Results
Generation of an NF1 minipig by gene editing. To generate a
minipig model of NF1, we mimicked a recurrent nonsense
mutation p.Arg1947*(R1947*) identified in 62 of 8100 (±8)
unrelated and symptomatic NF1 patients (Supplementary
Table 1)31. This mutation has also been described in several other
studies32–36. NF1R1947 lies within exon 41 of the swine NF1 gene,
which shares 100% amino acid identity with human exon 39
(Fig. 1a)37. Transcription activator-like effector nucleases
(TALENs) flanking NF1R1947 were transfected into fetal Ossabaw
minipig fibroblasts with a homology directed repair (HDR) oli-
gonucleotide containing the R1947* mutation and a HindIII
restriction fragment length polymorphism (RFLP) site (Fig. 1b,
Supplementary Table 2). Colonies derived from single cells were
isolated and genotyped for the NF1R1947* mutation (Fig. 1c).
Heterozygous clones were subjected to chromatin transfer
resulting in two viable pregnancies and eight F0 male piglets.
NF1R1947*/+ (NF1) F0 minipigs were sequence validated, subse-
quently bred to wild-type sows and exhibited germ line trans-
mission of the mutant NF1 allele with Mendelian frequency. A
total of 105 F1 piglets were produced from the first 15 litters: 54%
(57) wild type and 46% (48) NF1, with no evidence of reduced
fitness in NF1 minipigs. Germ line transmission of the mutant
NF1 allele was also demonstrated by breeding NF1 females to
wild-type males.
NF1 minipigs display CALMs and other skin abnormalities.
From birth, all NF1 F0 and F1 minipigs displayed multiple flat,
dark brown skin patches resembling NF1-associated CALMs, one
of the most common phenotypes in NF1 patients (Fig 1d, e,
Table 1). Histologically, CALMs showed hyperpigmentation of
the basal layer of the epidermis, as seen in humans (Fig. 1f, g).
One hundred percent of NF1 minipigs harbored six or more
CALMs over 5 mm pre-puberty or 15 mm post-puberty, as sti-
pulated in the National Institute of Health (NIH) diagnostic
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criterion for NF138. CALMs observed in NF1 minipigs increased
in size and number with age. A subset of NF1 minipigs exhibited
other abnormalities described in NF1 patients, including freck-
ling (30.8%, 4/13 animals) and congenital hypopigmentation
of the hair, with no underlying melanin changes in the skin
(23.1%, 3/13 animals) (Supplementary Figure 1, Table 1)1,4,5. In
contrast, no wild-type minipigs showed CALMs or evidence of
pigmentation defects (N > 50).
NF1 minipigs develop neurofibromas. Neurofibromas are
benign peripheral nerve sheath tumors composed of multiple cell
types including Schwann cells, fibroblasts, and mast cells39. These
tumors are variable in size and number and represent a major
source of pain and disfigurement in NF1 patients. Superficial
tumors resembling neurofibromas were noted in 40% (2/5) of the
NF1 F0 animals and 37.5% (3/8) of the NF1 F1 minipigs by
4 months of age (Table 1). Tumors were discrete and ranged
in number from one to six per animal and in size from 1.8 to
6.0 centimeters in diameter (Fig. 2a–c). Hematoxylin and eosin
(H&E) staining revealed areas of hypercellularity, confirmed to
be clusters of Schwann cells by S100β and glial fibrillary acidic
protein (GFAP) staining, surrounded by dense collagen and
sparse fibroblasts (Fig. 2d, e, g). These tumors had a low Ki67
proliferative index and showed mast cell infiltration (Fig. 2f, h, i).
Control immunohistochemistry was performed on sciatic nerve
and intestinal tissue (Supplementary Figure 2). These data show
that the tumors seen in NF1 minipigs share classic features of
human neurofibromas. The skin-related abnormalities seen in
NF1 minipigs closely resemble those seen in NF1 patients, and
this model meets the NIH criteria for both CALMs and neuro-
fibromas used to diagnose NF1 patients.
NF1 minipigs develop OPG. OPGs occur in 15–20% of children
with NF1, where >80% are located within the optic nerves and
chiasm1,6,40–42. These slow-growing benign tumors are typically
identified by magnetic resonance imaging (MRI), often revealing
focal enlargement of the optic nerve and/or chiasm42–44. One
of seven NF1 minipigs imaged by MRI for OPG development
exhibited a mass involving the optic chiasm that extended
ventrally into the surrounding tissue (Fig. 3a, b, Table 1). His-
topathology of this lesion revealed hypercellularity, microglial
infiltration, and a low Ki67 proliferative index, similar to OPGs
reported in NF1 patients and genetically engineered mouse
models (Fig. 3c–k)21,42,44–47.
Cells from NF1 minipigs undergo loss of heterozygosity.
Bi-allelic inactivation of the NF1 gene through a “second-hit”
mutation in a subset of Schwann cells has been demonstrated in
neurofibromas from human patients48–51. This phenomenon has
also been described in melanocytes isolated from CALMs50,52.
To evaluate this in our minipig model, CALM-derived melanocytes
and neurofibroma-derived Schwann cells were subjected to DNA
sequencing. LOH at the NF1 locus was detected in a subset
of CALMs and neurofibromas, by either a gene conversion event
or large deletion (Fig. 4a). Interestingly, one CALM showed
conversion to R1947* without RFLP incorporation, suggesting
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Fig. 1 Development of NF1 minipigs. a Human exon 39 and swine exon 41 of the NF1 gene show 100% amino acid homology. A pair of TALENs was
designed to bind swine NF1 exon 41 in the region of R1947. The entire exon is not shown; gray letters, differences in nucleotide sequences; bold letters,
TALEN-binding sites; blue letters, amino acid sequence. b The NF1R1947* allele was engineered into the swine genome using homologous recombination
(HR) of a 90mer HDR oligonucleotide containing a HindIII RFLP site to allow for facile analysis of HR-positive cells. Bold letters, TALEN-binding sites; red
italicized nucleotides, novel stop codon (R1947*); black italicized nucleotides, added nucleotides; blue letters, amino acids; red letters, amino acid code
resulting from frameshift. c Minipig embryonic fibroblasts were transfected with TALENs and HDR oligonucleotides and individual cells were isolated and
grown as single cell-derived colonies. These colonies were assayed for incorporation of the RFLP site by HindIII restriction enzyme digest followed by gel
electrophoresis. The closed arrowhead denotes the wild-type allele and the open arrowhead denotes the RFLP allele. Several clones were TOPO cloned and
sequenced to confirm the presence of both the wild-type allele and the NF1R1947* allele (clone 89 is shown as an example). Three to five sequence-
confirmed NF1R1947*/+ clones were pooled and underwent chromatin transfer to produce F0 NF1 male minipigs that were subsequently bred to wild-type
females to produce F1 minipigs. d A representative example of a CALM (white arrow) seen in an NF1 minipig at 5 months of age. e An example of multiple
CALMs seen in an NF1 minipig at 16 months of age. Scale bar, 2 cm. f H&E staining of adjacent normal NF1 minipig skin and wild-type minipig skin (shown
here) shows vascular beds (squares) and melanin but no melanin deposits. Scale bar, 200 µM. g H&E staining of CALMs shows melanin deposits in the
basal layer of the epidermis (black arrowheads). Scale bar, 200 µM
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partial gene conversion or a point mutation in the wild-type allele
(Fig. 4b). Schwann cells were subjected to western blot analysis
for neurofibromin protein expression, which confirmed the
DNA sequencing results in Schwann cells isolated from tumors
(Fig. 4c, d). To validate the biochemical defect in Ras signaling
associated with NF1 loss, Schwann cells from neurofibromas
or sciatic nerves were starved overnight, serum stimulated, and
analyzed by western blot for active Ras (Ras-GTP). Variable
levels of Ras activation were seen in Schwann cells isolated from
tumors with LOH compared to wild-type or NF1+/− Schwann cells,
despite >90% purity in Schwann cell cultures (Supplementary
Figure 3).
NF1 minipigs display other NF1-associated phenotypes. Elec-
tron microscopy (EM) of NF1 minipig optic nerves showed
myelin decompaction, a phenotype observed in mouse models
and correlated with white matter enlargement and behavioral
deficits in NF1 patients53,54 (Supplementary Figure 4). Lesions
resembling iris hamartomas, or Lisch nodules, were noted in
two of the three NF1 minipigs examined by slit-lamp (Table 1,
Supplementary Figure 5). Tibial diaphyseal narrowing was
observed in 15.4% (2/13) of NF1 minipigs that underwent X-ray
analysis (Table 1, Supplementary Figure 5). Blood pressure,
weight, height, length, and head circumference were measured
periodically in a cohort of NF1 minipigs and their wild-type
littermate controls (Supplementary Figure 6). At 8 months of
age, NF1 minipigs weighed significantly less than their wild-type
siblings. All 12 NF1 minipigs (five F0 animals and seven F1
animals) that underwent MRI analysis also underwent full-body
computerized tomography (CT) scanning and no other tumors
were observed (Table 1).
NF1 minipigs as a preclinical model for pharmacology studies.
It is useful to have a large animal disease model for testing
safety and efficacy of novel pharmaceutical compounds prior to
human studies. To demonstrate that NF1 minipigs represent a
relevant preclinical model, we performed pharmacokinetic and
pharmacodynamic analysis of PD0325901, a MEK inhibitor cur-
rently in clinical trials for NF1-related tumors (clinicaltrials.gov). A
single dose of 0.79mg kg−1 PD0325901 was administered orally to
four wild-type and four NF1 littermates and plasma was collected
over time for pharmacokinetic analysis. PD0325901 was detectable
in the plasma within 1 hour of administration, and the
mean maximum plasma concentration of PD0325901 was 125 ±
47 ngmL−1, a value higher than the reported PD0325901 plasma
concentration (99 ngmL−1) required for a pharmacodynamic effect
in other preclinical models (Fig. 5a)55. Notably, NF1 minipigs
showed significantly higher plasma levels of PD0325901 than their
wild-type littermate controls at 8 h (wild-type 59 ± 30 ngmL−1 vs.
NF1 104 ± 15 ngmL−1) and 10 h (wild-type 48 ± 20 ngmL−1 vs.
NF1 87 ± 15 ngmL−1) after drug administration, though estimated
pharmacokinetic parameters showed no statistically significant
differences between wild-type and NF1 minipigs (Fig. 5a, Supple-
mentary Table 3). To measure the pharmacodynamic effect of
PD0325901 in minipigs, peripheral blood mononuclear cells
(PBMCs) were evaluated for suppression of phorbol-myristate acid
(PMA)-stimulated ERK phosphorylation, a pharmacodynamic
biomarker of MEK inhibitors56,57. A single dose of PD0325901 was
sufficient to suppress ERK phosphorylation in PBMCs by 98.1%
(±0.7) in NF1 minipigs and 95.8% (±1.2) in wild-type minipigs
(Fig. 5b). These results suggest that NF1 minipigs could serve as a
valuable preclinical model for pharmacokinetic and pharmacody-
namic analysis of targeted therapies.
Table 1 Summary of NF1-related phenotypes seen in NF1 minipigs that underwent imaging
Animal
ID
Generation Sex Age Imaging CALM Freckling Lisch
nodules
Hypopigmentation Neurofibroma OPG Tibial diaphysis
narrowing
1728 F0 M 5.3 months MRI, CT,
X-ray
Present Absent N/A Absent Absent N/A Bilateral
1729 F0 M 19.8 months MRI, CT,
X-ray
Present Absent Absent Absent Several in
armpit region
N/A Absent
1730 F0 M 16.7 months MRI, CT,
X-ray
Present Absent Present Present Absent N/A Absent
1734 F0 M 3.7 months MRI, CT,
X-ray
Present Absent N/A Absent Absent N/A Bilateral
1735 F0 M 19.8 months MRI, CT,
X-ray
Present Absent Present Absent Several in
armpit region
N/A Absent
1228 F1 F 9.0 months MRI, CT,
X-ray
Present Absent N/A Absent Absent Present Absent
1229 F1 M 16.1 months MRI, CT,
X-ray
Present Absent N/A Absent Several in
armpit region
Absent Absent
3 discrete
tumors
1232 F1 M 15.7 months MRI, CT,
X-ray
Present Present N/A Present Several in
armpit region
Absent Absent
5 discrete
tumors
1233 F1 M 8.9 months MRI, CT,
X-ray
Present Present N/A Absent Absent Absent Absent
1236 F1 F 9.0 months MRI, CT,
X-ray
Present Present N/A Present Absent Absent Absent
1342 F1 F 8.8 months MRI, CT,
X-ray
Present Absent N/A Absent Absent Absent Absent
1346 F1 M 9.9 months X-ray Present Present N/A Absent Absent N/A Absent
1359 F1 F 9.9 months MRI, CT,
X-ray
Present Absent N/A Absent 1 discrete
tumor
Absent Absent
Prevalence of phenotype 13/13 4/13 2/3 3/13 5/13 1/7 2/13
N/A not assessed
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Fig. 2 NF1 minipigs develop neurofibromas. a An example of an NF1 minipig harboring two dermal masses on its left side. The mass denoted by the white
dotted box is enlarged in b and the mass denoted by the solid white box is enlarged in c. b The mass on the shoulder measured 3.5 cm in diameter. c The
mass on the flank measured 4.2 cm in diameter. d H&E staining of a representative mass showing regions of hypercellularity. e Hypercellular regions stain
positive for GFAP, a marker of Schwann cells. f Mast cell infiltration is shown by Toluidine blue metachromasia (purple). g Hypercellular regions stain
positive for S100β, a marker of Schwann cells. h Hypercellular region showing minimal proliferation by Ki67 staining. i Mast cell infiltration is shown by
c-Kit staining. Scale bars, 100 µM
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Fig. 3 NF1 minipigs develop optic pathway glioma-like lesions. a Axial T1-weighted MRI demonstrates a lesion at the level of the optic chiasm (white arrow)
in a 9-month-old NF1 minipig. b Axial T1-weighted MRI of a normal optic chiasm from a 16-month-old NF1 minipig. c H&E staining of the optic pathway
lesion from an NF1 minipig shows hypercellularity. d H&E staining of an optic nerve from an NF1 minipig. e H&E staining of an optic nerve from a wild-type
minipig. f Iba1 immunohistochemistry of the optic pathway lesion from an NF1 minipig shows increased microglial infiltration. g Iba1 immunohistochemistry
of an optic nerve from an NF1 minipig. h Iba1 immunohistochemistry of an optic nerve from a wild-type minipig. i Ki67 staining of an optic pathway lesion
from an NF1 minipig shows a low proliferative index. j Ki67 staining of an optic nerve from an NF1 minipig. k Ki67 staining of an optic nerve from a wild-type
minipig. Scale bars, 50 µM
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Discussion
We describe here, the first minipig model of NF1 that exhibits
the spectrum of clinical features seen in patients. NF1 minipigs
meet NIH diagnostic criteria for NF1, and a subset of minipigs
develop neurofibromas and OPG. This is also the first animal
model of NF1 to exhibit CALMs, one of the most common
clinical manifestations in humans. Both melanocytes and
Schwann cells from NF1 minipigs undergo spontaneous LOH, a
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Fig. 4 A subset of CALM-derived melanocytes and neurofibroma-derived Schwann cells show loss of heterozygosity. a The chromatogram trace peak
area of T nucleotides at the level of the R1947* point mutation (CGA (R)→TGA (*)) relative to total trace peak area is displayed as the percentage of
T nucleotides. Samples with >75% percent T nucleotides were considered to have undergone LOH. Samples with less than 75% T nucleotides were
considered to have retained the wild-type allele. 4/8 melanocyte cultures derived from CALMs and 6/11 Schwann cell cultures from neurofibromas show
LOH. In contrast, none of the six fibroblast cultures isolated from normal NF1 minipig skin (NF1+/− fibroblasts) show LOH. b Sanger sequencing shows
various mechanisms of LOH. An example chromatograph of a wild-type allele and R1947* RFLP allele isolated by TOPO cloning and sequenced are shown
at the top. Melanocytes isolated from a CALM from NF1 minipig 1359 show complete conversion to the RFLP allele as seen by PCR population allele
sequencing. Melanocytes isolated from a CALM from NF1 minipig 1413 show LOH with incorporation of the NF1R1947* mutation, but not the HindIII RFLP
site, as seen by TOPO cloning. c Five Schwann cell lines from NF1 minipig neurofibromas (tumors 1–5) with LOH show loss of neurofibromin protein
expression. This western blot was cropped to improve the conciseness of the presentation. The full-length blot is presented in Supplementary Figure 7. This
western blot is representative of three experiments. d Relative density quantification of neurofibromin protein expression to α-tubulin. Wild-type Schwann
cells from wild-type minipig sciatic nerve, NF1+/− Schwann cells from NF1 minipig sciatic nerve, NF1−/− immortalized human NF1−/− Schwann cell line
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Fig. 5 The NF1 minipig as a preclinical pharmacology model. a Plasma concentration-time plot of PD0325901 in wild-type (n= 4) and NF1 (n= 4) minipigs
following a single dose of PD0325901 administered orally at 0.79mg kg−1. Error bars represent standard deviation of the mean. b Relative levels of p-ERK
in isolated PBMCs from wild-type and NF1 minipigs are shown. Whole blood was collected before (pre-PD0325901) and 4 h after (post-PD0325901) drug
administration, then stimulated with PMA ex vivo to induce MAPK pathway activation in PBMCs. PD0325901 suppressed ERK phosphorylation by >90%
in PBMCs within 4 h in both wild-type (n= 4) and NF1 (n= 3) minipigs. Lines represent mean with standard deviation. Statistical analysis: n.s.—not
significant, *P= 0.03, **P= 0.01, paired t-test. The full-length blot is presented in Supplementary Figure 8
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critical step in disease progression. To our knowledge, sponta-
neous LOH in the cells of origin of neurofibroma and CALM has
not been demonstrated in any other animal model of NF1.
Interestingly, porcine Schwann cells with LOH show variable
evidence of hyperactive Ras signaling in vitro. This may be
indicative of a more complex biochemical process associated with
NF1 loss in neurofibromas, such as activation of dual specificity
phosphatases39.
Similar to the human condition, our model shows variability
in expression of NF1 phenotypes. For instance, NF1 minipig
CALMs vary greatly in size and number between animals.
Additionally, only a subset of minipigs develop OPG and neu-
rofibromas. A clear strength of our system is that the NF1 minipig
closely mimics the age of onset for NF1-related phenotypes in
humans. In humans, CALMs are often present at birth, and
neurofibromas tend to develop around puberty. CALMS were
observed perinatally in all pigs, and minipig neurofibromas
develop at around 4 months of age (puberty ~5–6 months). While
OPG is typically diagnosed at a young age in humans, this phe-
notype was not noted in the NF1 minipig until 9 months of age
(adulthood). However, it is likely that OPG was present at a
young age and could not be diagnosed until MRI was performed,
as these tumors are often asymptomatic.
While various model systems have been implemented to
induce tumor development in mice, these have not proven
to be representative of the complex natural history of NF1-
associated tumorigenesis20,21. For example, Nf1+/− mice do
not develop peripheral nerve sheath tumors or other hall-
marks of NF1 syndrome (Table 2)22,23. Interestingly, a subset
will develop less common NF1-associated tumors later in life,
including neurofibrosarcoma, pheochromocytoma, and mye-
loid leukemia22,23. It is possible that we would see these
manifestations in the NF1 minipig, but Ossabaw minipigs
have a lifespan of up to 15 years in captivity and were only
monitored for 16 months for the purposes of this study. In
comparison to the analogous mouse model described by Jacks
et al.22 and Brannan et al.23, our NF1 minipig model manifests
the more common hallmarks of the disease (Table 2). In fact,
the original Nf1+/− mouse models share no phenotypes with
our NF1+/− minipig model (Table 1).
The genetic, anatomic, and physiologic similarities between
minipigs and humans make them an optimal model for studying
the biology and natural history of NF1. The minipig provides a
human-sized platform for imaging studies to better evaluate
tumor natural history and therapeutic efficacy and to develop
methods for early detection of NF1-associated tumors. Their
large size also makes it feasible to perform longitudinal blood and
tissue sampling for identification of diagnostic biomarkers and
evaluation of NF1-targeted therapies. The NF1 minipig may prove
particularly valuable for studying long-term toxicity of targeted
therapies in both pediatric and adult populations, as many drug-
gable targets show significant homology between pig and human.
Further, this model provides the opportunity to evaluate drug
penetrance through the blood–nerve and blood–brain barriers.
These studies will be critical in evaluating efficacy of treating NF1-
related tumors including neurofibromas and OPGs.
Thus far, other important NF1-associated tumors including
plexiform neurofibromas, malignant peripheral nerve sheath
tumors, and gastrointestinal stromal tumors have not been observed
in our model. We will continue monitoring NF1 minipigs as they
age for the development of these and other clinical manifestations.
To model more aggressive phenotypes, the NF1 minipig could be
augmented with additional germ line or somatic mutations. For
example, Tumor Protein p53 (TP53), a tumor suppressor gene that
is often found co-mutated with NF1 in malignant peripheral nerve
sheath tumors, is in close proximity to the NF1 gene (~9MB) in the
swine genome. This allows for the development of a minipig in
which both NF1 and TP53 are mutated in cis, similar to previously
described mouse models of malignant peripheral nerve sheath
tumors58,59. Swine also harbor the Polycomb Repressive Complex 2
Subunit (SUZ12) gene, which is recurrently inactivated in NF1-
associated malignancies and could be mutated or deleted with NF1
to drive the formation of additional tumor types. Future studies
will also evaluate NF1-associated cognitive deficits and neuro-
developmental disabilities in our minipigs60,61. We predict that our
NF1 minipig model will ultimately accelerate treatment options
for patients and serve as a platform for studying the natural history
of this intractable disease.
Methods
TALEN design, assembly, and RNA synthesis. All TALENs were designed using
the TALE-NT software and assembles using standard methods62. Linearized
TALEN DNA was transcribed in vitro using the mMessage Machine T3 kit
(Ambion). Synthesis reactions were assembled in a 20 µL reaction with 1 µg line-
arized plasmid DNA, 1× NTP/CAPs (Ambion), 1× reaction buffer (Ambion), and
2 µL enzyme mix (Ambion). Reactions were incubated for 2 h at 37 °C, treated with
Turbo DNase (Invitrogen), then cleaned up with the RNeasy Mini Kit (Qiagen).
Cell culture and transfection of swine embryonic fibroblasts. Ossabaw minipig
fibroblasts isolated from day 30–36 embryos were cultured in 1× high-glucose
DMEM (Invitrogen) with 10% FBS (Atlas Biologicals), 2 mM L-glutamine
(Corning), 10 mM HEPES buffer (Lonza), 1× penicillin/streptomycin solution
(Corning), 5 µg mL−1 Apo-Transferrin (Sigma), 20 ng mL−1 recombinant human
IGF-1 (R&D Systems), and 25 ng mL−1 recombinant human EGF (R&D Systems)
and transfected using the Neon Transfection System (Thermo Fisher Scientific).
Briefly, each transfection reaction included 600,000 fibroblasts, 0.5 μg of RNA from
each transcribed TALEN, and 0.2 nmol HDR oligonucleotide, and the transfection
reaction was pulsed once at 1800 V for 20 ms using the Neon™ transfection system
(Thermo Fisher Scientific). Transfected cells were cultured 3 days at 30 °C, before
splitting for RFLP analysis and plating for colony isolation at 38.5 °C. Individual
colonies were collected in 10-cm dishes, where 80–250 transfected cells were plated
and allowed to grow for 10–14 days and individual colonies were aspirated under
gentle trypsinization.
Detection and sequence validation of gene modification. Transfected cells
harvested at day three were prepared for PCR by pelleting and resuspending in
PCR-safe lysis buffer (10 mm Tris·Cl, pH 8.0; 2 mM EDTA; 2.5% (vol/vol) Tween-
20; 2.5% (vol/vol) Triton X-100; 100 μg mL−1 proteinase K) at ∼1000 cells per μL,
Table 2 Comparison of mouse, minipig, and human NF1-associated phenotypes1,4,5,22,23,80
NF1 animal model Age at
puberty
Lifespan Average age of onset
OPG Cutaneous
neurofibroma
Lisch
nodule
CALM Pheochromocytoma Myeloid
leukemia
Tibial diaphyseal
narrowing
Mouse
(Mus musculus)
6–8 weeks 1–3
years
n/a n/a n/a n/a 15–28 months 17–27 months n/a
Ossabaw minipig
(Sus scrofa)
5–6 months 15 years 9 months 4 months Pre-
puberty
Birth n/a n/a Pre-puberty
Human 10–15 years 70–80
years
3–5 years 10–15 years Pre-
puberty
Birth 39 years 2 years 6–12 months
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followed by incubation at 50 °C for 60 min and 95 °C for 15 min. Typically, 1 μL of
prepared lysate was used in a 2× AccuStart II PCR SuperMix (QuantaBio); all other
applications were according to the manufacturer’s protocol. Gene modification
in individual colonies was detected by RFLP analysis and direct sequencing of
PCR amplicons, characterized by TOPO cloning (Invitrogen) and sequencing.
Animal husbandry and cloning. NF1 minipigs were produced under license
of chromatin transfer technology from Hematech to Cooperative Resources
International Center for Biotechnology (CRI_ICB), Verona, WI)63. All animal
work was performed in Recombinetics facilities under its Animal Welfare
Assurance #A4728-01 and the University of Minnesota under its Animal Welfare
Assurance #A3456-01. All animal protocols were reviewed and approved by the
Institutional Animal Care and Use Committee (IACUC).
H&E, toluidine blue, and immunohistochemical staining. H&E staining was
performed on 3.5-µM-thick sections prepared from paraffin blocks of formalin-
fixed tissues. For mast cell staining, a toluidine blue stock solution (10×) was
prepared by diluting 1 g of toluidine blue O (Fisher Chemical, T161) in 100 mL of
ethanol 70%. The stock solution was freshly diluted in sodium chloride 1% with pH
adjusted to 2.0–2.5 with glacial acetic acid. Sections were immersed in toluidine
blue solution for 3 min, rinsed three times in distilled water, then quickly
dehydrated and cleared in Clear-Rite (Thermo Scientific) before mounting. For
immunohistochemistry, heat-induced epitope retrieval (HIER) was performed with
target retrieval solution pH9 (Dako, S2367) except for S100β staining where no
HIER was used. A standard protocol was used with primary antibodies incubated
1 h at room temperature (RT): c-Kit (1:200, Cell Signaling Technology, #3074),
GFAP (1:3000, Dako, Z0334), Ki-67 (1:1000, BD Pharmingen, 556003), S100β
(1:10000, Dako, Z0311). Biotinylated secondary anti-rabbit (1:2000 or 1:50,000),
anti-mouse (1:5000 Vector Laboratories, Burlingame, CA) IgG antibodies were
incubated 30 min at RT. Pictures were taken with an Axio Imager M1 microscope
and Axiovision software (Zeiss).
Minipig sedation, radiographic imaging, and euthanasia. Pigs were transported
to the University of Minnesota Veterinary Medical Center (VMC) for housing and
radiographic imaging. Minipigs were housed in stalls or kennels sized per the
Guide for the Care and Use of Laboratory Animals. Minipigs were housed
individually, fed a standard pig diet, and allowed water. Minipigs were fasted for
12–18 h prior to anesthesia.
Anesthesia was induced with telazol (2.2–4.4 mg kg−1), xylazine (2 mg kg−1),
±ketamine (20 mg kg−1) intramuscularly (IM), then the animals were intubated
with balloon-cuffed 7.5–10 mm endotracheal tubes. Anesthesia was maintained
with 1–5% isoflurane. Minipigs were mechanically ventilated at 100% oxygen with
a volume of 340–1000 mL (depending upon size) and pressure 15–22 cm water, to
maintain an end tidal CO2 of 35–45 mmHg. An 18–22-gauge IV catheter was
placed in a peripheral ear vein or cephalic vein for administration of IV fluids and
euthanasia solution. IV fluids (Lactated Ringers Solution or 0.9% saline) were given
to minipigs that had multiple imaging procedures. Pulse, respirations, blood
oxygen saturation, CO2 level, and blood pressure were monitored continuously and
recorded every 5–15 min.
Once anesthetized, minipigs were transported to the desired imaging area:
X-ray, CT, or MRI. Typically, minipigs receiving all three modalities would start in
CT, move to MRI, then to X-ray. The bore of the MRI limited the size of minipigs,
which could be scanned. Therefore, minipigs over 90 kg were imaged by CT, then
X-ray, then MRI of the head only post-mortem.
CT acquisition: minipigs were placed in the supine position and a single, non-
contrast enhanced dataset of the chest–abdomen–pelvis region was acquired using
a Toshiba Aquilion-64 CT scanner (Toshiba Medical Systems, software version
V3.35ER006). Images were acquired in a helical mode using the full 64-row
detector at an image thickness of 0.5 mm, with a standard technique of 120 kV,
200 mAs, 0.5 s rotation time, pitch factor of 0.828, convolution kernel FC03. The
raw image dataset was reconstructed into 2.0 mm thick by 2.00 mm image interval
datasets in three separate convolution kernels to accentuate soft tissue (FC03), bone
(FC30), and lung parenchyma (FC52).
MRI acquisition: MRI data were obtained on a GE Signa HDxT 3.0T MRI
system (GE Medical Systems, software version HD 16.0_V03_181638.a). Brain
sequences: The minipig was placed in supine position and imaged using a
cervical–thoracic–lumbar (CTL)-phased array coil. An initial set of T2-weighted
images of the skull in the sagittal, coronal, and transverse planes (TR: 3000–7000
ms; TE: 123–125 ms; echo train length: 1; flip angle: 90°; resolution: 5.0 mm slice
thickness × 1.8 mm) were acquired. This was followed by a T2 Fluid Attenuation
Inversion Recovery (FLAIR) dataset in the coronal plane (TR: 8000 ms; TE:
100–102 ms; echo train length: 24; flip angle: 90°; inversion time: 2250 ms;
resolution: 5.00 mm slice thickness × 1.8 mm spacing), a T1-weighted dataset of the
same area (TR: 600–1000 ms; TE: 123–125 ms; echo train length: 1; flip angle: 90°;
resolution: 5.0 mm slice thickness × 1.8 mm spacing), and an oblique-coronal T2
with fat saturation dataset, angled to image approximately parallel with the
optic nerve, (TR: 8000 ms; TE: 100–102 ms; echo train length: 24; flip angle: 90°;
inversion time: 2250 ms, resolution: 3.0 mm slice thickness × 0.3 mm spacing).
An oblique-coronal T1 dataset of the same images was also acquired
(TR: 600–1000 ms; TE: set to min full; echo train length: 3; resolution: 3.0 mm slice
thickness × 0.3 mm spacing). In some minipigs, a 3D T1 (fast spoiled gradient
echo) sequence was obtained (TR: variable; TE: set to min full; prep time: 450 ms;
flip angle: 12; resolution: 1.0 mm × 1.0 mm × 1.2 mm slice thickness). Spine
sequences: short-tau inversion recovery images of the cervical, thoracic, and lumbar
spine were acquired in the sagittal plane (TR: 3000–7000 ms; TE: 25–55 ms;
echo train length: 10–12; flip angle: 90°; inversion time: 190 ms; resolution: 3.0 mm
slice thickness × 0.3 mm spacing). Transverse T2 images with fat saturation were
acquired (TR: 8000 ms; TE: 100–102 ms; echo train length: 24; flip angle: 90°;
inversion time: 2250 ms, resolution: 5.0 mm slice thickness × 3.0 mm spacing).
Transverse T1-weighted images were acquired (TR: 600–1000 ms; TE: 123–125 ms;
echo train length: 1; flip angle: 90°; resolution: 5.0 mm slice thickness × 3.0 mm
spacing). Dorsal 3D T2 with fat saturation images were acquired (TR: 2500 ms;
TE: 101 ms; echo train length: 100; flip angle: 90°; resolution: 1.0 mm × 1.0 mm ×
1.0 mm).
Radiographs of minipigs under 40 kg were imaged using the VMC Small
Animal Digital X-ray (Sedecal Vet-X Technology) digital radiograph system: RAD
positional, high frequency generator, Toshiba Rotanode tube E7-23X, software
Vieworks Co. Ltd. VXvue version 1.0.0.82b10, DR detector: ViviX 17 × 17 digital
panel, amorphous silicon sensor (a-SI) high speed Gadox scintillator, 140-μm pixel
pitch, 9.2 million pixels (3008 × 3072), 4096 gray scale (14 bits A/D). Images taken
were of the entire spine, cervical to sacrum, lateral and ventrodorsal (VD), and
both hind legs (tibia or tibia/fibula with two views (VD and lateral)). Imaging
parameters were stored as a part of the DICOM information with each image.
Radiographs of minipigs over 40 kg were imaged using the VMC Large Animal
X-ray: (Varian Medical Systems Tube (2016, type RAD-44, housing mode
“Sapphire”); Acoma tower, Shimadzu control unit). Images taken were of the entire
spine, cervical to sacrum, lateral and VD, and both hind legs (tibia or tibia/fibula
with 2 views (VD and lateral)). Imaging parameters used were based upon size and
resulting quality, with a range of 84–110 peak kilovoltage (KVP), 500–630 mA,
and 100–250 mAs. X-ray images were captured on cassette and read into PACS
(Picture Archiving and Communication System).
Following imaging, the minipigs were transported to the Veterinary Diagnostic
Laboratory (VDL) for euthanasia and necropsy. Prior to transport, an IM dose
of telazol (2.2 mg kg−1), xylazine (1 mg kg−1), and ±ketamine (10 mg kg−1)
was given.
Optic pathway immunohistochemistry and pathological analysis. Formalin-
fixed paraffin-embedded sections were subjected to immunohistochemistry using
cell-type-specific antibodies64. The optic nerves and chiasms were dissected from
euthanized animals and fixed in formalin prior to paraffin embedding and
sectioning. Five-micrometer sections were deparaffinized, treated for citrate antigen
retrieval, and incubated in 5% serum blocking solution for 1 h at RT. Slides were
next incubated with Iba1 (1:1000 dilution; WAKO; 019–19741) or Ki67 (1:1000
dilution; Abcam; ab15580) primary antibodies overnight at 4 °C, followed by a 1-h
exposure to biotinylated species-specific secondary antibodies (Vector Labora-
tories) and development using the Vectastain Elite ABC kit (Vector Laboratories)
according to the manufacturer’s instructions. H&E staining was accomplished
using standard methods. Images were acquired on an Olympus BX51 microscope
using cellSens Entry imaging software.
Isolation and culture of primary minipig cell lines. Minipig skin fibroblasts were
isolated from ear clips transported in 1× HBSS (Corning) with 1× antibiotic/
antimycotic (AA; Corning). Hair and subcutaneous fat were trimmed from
specimens, rinsed in 1× phosphate-buffered saline (PBS, Invitrogen) with 1× AA,
then lathered with povidone-iodine (Betadine). Specimens were transferred into a
series of tubes beginning with 70% ethanol and three sets of 1× PBS with 1× AA
washes. Underlying hypodermis was trimmed and discarded using sterile forceps
and scalpel. Tissues were minced and transferred to a conical tube containing full
growth media (1× high-glucose DMEM (Invitrogen) supplemented with 10% FBS
(Atlas Biologicals), 2 mM L-glutamine (Corning), 10 mM HEPES buffer (Lonza),
1× penicillin/streptomycin solution (Corning), 5 μg mL−1 Apo-Tranferrin (Sigma),
20 ng mL−1 recombinant human IGF-1 (R&D Systems), and 25 ng mL−1
recombinant human EGF (R&D Systems)), 200 UmL−1 collagenase, and 1× AA
and incubated at 37 °C on a tube rotator for 16 h. Fibroblasts were centrifuged at
300×g for 10 min followed by two washes in 1× PBS and centrifugation repeated.
Cells were resuspended in full growth media containing 1× AA, counted with a
hemocytometer, and plated at 2.8 × 104 cells per cm2 with media changes every
3 days.
Isolation of porcine Schwann cells was adapted from a protocol for human
Schwann cells65. Porcine sciatic nerves (1–2 inches) were removed upon euthanasia
and placed immediately in ice-cold DMEM with antibiotic–antimycotic (GIBCO),
then transported to the laboratory within 2 h. Nerves were cut into 1 cm3 pieces
and incubated at 37 °C, 5% CO2 in pre-treatment medium (PM) containing
DMEM with high glucose (GIBCO) supplemented with 10% fetal bovine serum
(FBS) (GIBCO), gentamicin (50 mgmL−1) (GIBCO), fungizone (2.5 mgmL−1)
(GIBCO), forskolin (2 μM) (Calbiochem), and recombinant neuregulin-b1 (NRG1)
(10 ng mL−1) (R&D Systems). Pre-treatment medium was replaced every 2 days.
After 7 days, nerves were dissociated for 3–5 h in DMEM containing 10% FBS,
collagenase type I (130 UmL−1) (GIBCO), dispase II (2.5 mg mL−1) (Roche),
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gentamicin (50 mgmL−1), fungizone (2.5 mg mL−1), penicillin–streptomycin
(GIBCO), at 37 °C. Nerves were then mechanically dissociated by trituration using
a 5 mL pipet, then centrifuged for 10 min at 1000 r.p.m., resuspended in PM, and
incubated at 37 °C, 5% CO2 on poly-L-lysine and laminin-coated plates. To coat
plates, poly-L-lysine (0.05 mgmL−1) (Sigma) was applied for 30 min at RT, then
removed and then plate washed three times with PBS. Mouse laminin (10 mgmL
−1) (GIBCO) was applied for 1 h at RT, then removed and replaced with DMEM
and 10% FBS for 30 min at RT. Plates were kept in PBS until use. Media was
changed every 2–3 days and cells were passaged when they reached 90% confluence
and seeded in fresh coated plates at 30,000 cells per mL. Geneticin (G418)
(Corning, 100 μg mL−1) was added to cultures for 48 h to eliminate contaminating
fibroblasts66. G418 treatment was performed up to two times with a 1-week rest
period between treatments. Schwann cells were cryopreserved in DMEM with 20%
FBS and 10% dimethyl-sulfoxide (DMSO) (Sigma). Schwann cells were isolated
from tumors as above, with minor modifications. Epidermal tissue was discarded
and tumor tissue (4 mm–2 cm) was cut into ~5 mm3 pieces and incubated for
7 days in PM, then incubated overnight in dissociation media. Tumor-associated
fibroblasts were prominent and relatively resistant to G418 treatment and were
therefore removed by differential trypsinization, colony picking, serum-free media,
or magnetic cell separation according to the manufacturers protocol using an anti-
NGFR antibody and positive selection (eBioscience 50-112-2782)65. For differential
trypsinization, cells were washed with PBS and then incubated for 1–2 min in
0.05% trypsin diluted in PBS (Gibco). The supernatant was removed, and
remaining cells were harvested with 0.25% trypsin. These cells were counted and
re-seeded onto fresh coated plates.
Isolation and growth of porcine melanocytes was adapted from the human
protocol67. Skin biopsies of 1 cm3 were incubated overnight in 10 mgmL−1 dispase
II (Boehringer Mannheim) to separate epidermis from dermis. Epicutaneous sheets
were carefully removed with forceps and dissociated for 10 min at 37 °C in 500 μg
mL−1 trypsin/EDTA. Melanocytes were cultured in media containing DMEM
high glucose supplemented with 10% FBS, 10 ng mL−1 porcine stem cell factor
(Kingfisher), 100 pM cholera toxin (Sigma), 200 nM 12-O-tetradecanoylphorbol-
13-acetate (TPA) (CST), and 10 nM endothelin-1 (BACHEM). Media was changed
every 2–3 days and fibroblasts were removed using G418, as for Schwann cell
cultures. Melanocytes were identified by morphology and pigmentation and were
considered pure when there was <5% fibroblast/keratinocyte contamination. While
there was often significant contamination in the first few days after dissociation,
most cultures were >99% pure after the first passage, as keratinocytes do not
survive under these growth conditions and fibroblasts were successfully eliminated
with G418 treatment.
NF1 LOH analysis. To measure LOH at the NF1 locus in tumor-derived Schwann
cell and CALM-derived melanocyte cultures, the trace peak area at the location of
the point mutation (C → T) was measured in each DNA sequencing chromatogram,
and the percent area of each peak compared to total area was calculated using the
following packages in R: plyr, magrittr, tidyverse, sangerseqR68–72. In heterozygous
cells, the percent of T alleles should be about 50% and was found to be between
50% and 57% in fibroblasts from normal NF1 minipig skin. In cells that have lost
the wild-type allele, the percentage of T nucleotides should be about 100%. DNA
isolated from tumor-derived Schwann cells and CALM-derived melanocytes ran-
ged from 44 to 95%, with a distinct gap between 64 and 80%. The cutoff for LOH
was therefore set at 75% T nucleotides to account for contamination with NF1+/−
cells and inherent limitations of the sequencing software73.
Western blotting. Cells were harvested in trypsin, washed once with 1× PBS,
snap-frozen in liquid nitrogen, and stored at −80 °C as dry pellets until analysis.
Cells were lysed in RIPA buffer (Sigma) containing phosphatase and protease
inhibitors (Sigma) and centrifuged for 15 min at 4 °C at 15,000 r.p.m. Supernatants
were used for analysis. Total protein concentration was estimated by BCA assay
(Pierce). Twenty micrograms of total protein was resolved on a 4–12% Nupage
Bis-Tris gel (Thermo) and transferred overnight at 4 °C to an immun-blot PVDF
membrane (Bio-Rad) using an XCell II Blot module (Thermo). Blots were blocked
for 1 h at RT in PBS supplemented with 0.1% Tween-20 (Sigma) and 5% non-fat
dry milk (Bio-Rad). Blots were cut into strips and incubated with primary antibody
overnight at 4 °C with rotation. Blots were then washed three times for 5 min and
incubated with secondary antibody for 1 h at RT. Blots were washed as described
and developed with WesternBright Quantum reagents (Advansta). Bands were
visualized using a Li-Cor Odyssey Fc Imaging System. Semi-quantitative levels of
each band were analyzed by densitometry using Li-Cor Image Studio software, and
the relative values normalized to α-tubulin are indicated numerically under each
lane. Antibodies used for this analysis were anti-neurofibromin (SCBT sc376886)74
or anti-α-tubulin (CST 2144)75, anti-mouse IgG HRP (Pierce 31431), and anti-
rabbit IgG-HRP (SCBT sc2313).
PD0325901 formulation and dosing. PD0325901 (Pfizer) was obtained from
SelleckChem (Houston, TX) and underwent testing at the University of Minne-
sota’s Institute for Drug Discovery for confirmation of molecular identity and
analysis of purity using an acetonitrile/water/formic acid liquid chromatography
(LC) conditions. PD0325901 was determined to be >99% pure by LC/mass
spectrometry (MS) and nuclear magnetic resonance spectroscopy (NMR) analysis.
PD0325901 was formulated for oral administration in aqueous 0.5% (w v−1)
methylcellulose solution with 0.2% (v/v) polysorbate 80 (Tween 80) to a
concentration of 4 mgmL−1 and sonicated to form a suspension. A single oral
dose was administered to four wild-type and four NF1 minipigs at 0.79 mg kg−1.
The required volume of drug for each animal was based on individual body weight
determined on the day of administration.
Pharmacokinetic analysis of PD0325901. Whole blood was collected from
the jugular vein into sodium heparin vacutainer tubes prior to PD0325901
administration (pre), and 1, 2, 4, 6, 8, 10, 12, 24, 36, and 48 h after PD0325901
administration. Samples (1.5 mL) were immediately transferred to a 1.7 mL
microfuge tube and centrifuged at 2000×g for 10 min in a tabletop refrigerated
centrifuge at 4 °C. Plasma was subsequently transferred to a cryovial and stored
at −80 °C until analysis.
Following the addition of an internal standard (30 ng of PLX4720), plasma
samples (0.15 mL) were extracted with 1.25 mL of ethyl acetate using a multi-tube
vortex for 10 min. Following centrifugation at 15,000×g for 5 min, the supernatant
was removed and evaporated to dryness using a nitrogen evaporator (Zymark
Turbo Vap LV, Hopkinton, MA) set at 37 °C. The residue was reconstituted
with 125 µL of mobile phase76.
Detection and quantification of PD0325901 was performed using a high-
performance liquid chromatograph (Agilent 1100 Series, Santa Clara, CA) coupled
with an API 4000 triple quadrupole instrument (MDS-SCIEX, Concord, Ontario,
Canada). The chromatographic separation was performed with a ACQUITY UPLC
BEH C18 column, 50 mm × 2.1 mm, 1.8 µm (Milford, MA) with a mobile phase
containing (40:60) DI water with 0.1% formic acid: acetonitrile with 0.1% formic
acid, at a flow rate of 250 µL min−1, with the column temperature set at 30 °C.
Mass spectrometric detection was performed using MRM (multiple reaction
monitoring) in negative ionization mode. Source conditions were as follows: the
turbo-gas temperature was set at 400 °C, and the ion spray needle voltage was
optimized at −4500 V. The mass spectrometer was operated at unit resolution
for both Q1 and Q3 in the MRM mode, with a dwell time of 100 ms per MRM
channel. The precursor/product ion pairs monitored were m/z 481–>398 for
PD0325901 and m/z 412–>305 for the internal standard (IS) (PLX4720). Ion
source gases 1 and 2 were set at 20 and 50 (arbitrary units), respectively; the curtain
gas was at 50 (arbitrary units) and the collision gas at 4 (arbitrary units). The
collision energy was set at −22 eV for PD0325901 and −38 eV for the IS. Data
acquisition was performed with analyst 1.4.1 software (MDS-SCIEX, Concord,
Ontario, Canada).
PD0325901 was obtained from MilliporeSigma (St. Louis, MO) and the internal
standard was obtained from Cayman Chemicals (Ann Arbor, Michigan). Minipig
plasma for calibrators and standards were obtained from Valley Biomedical
(Winchester, VA). The assay was linear in the range of 1–5000 ng mL−1, using 1/X
weighting. Method validation accuracy was 100.5% and the total variability was
6.8% (6.4% within day and 2.1% between days).
PD0325901 plasma concentration-time data from oral administration were
analyzed using noncompartmental methods as implemented in R (version 3.4.1)
R Studio PKNCA package (version 0.8.1)77. The pharmacokinetic parameters
included area under the concentration-time curve from time 0 to 48 h
(linear up, log down), maximum concentration (Cmax), time to Cmax (Tmax),
and half-life (t1/2).
Pharmacodynamic analysis of PD0325901. Blood samples were collected
immediately before PD0325901 administration and 4 h after PD0325901 admin-
istration. Whole blood was treated ex vivo with 200 nM 12-O-tetra-
decanoylphorbol-13-acetate or PBS for 10 min at 37 °C within 1 h of being drawn.
Peripheral blood mononuclear cells (PBMCs) were isolated, washed, and dry
pellets were snap-frozen and stored at −80 °C. Cells were lysed as described above.
Relative quantification of p-ERK to total ERK was completed using an automatic
Simple Western apparatus, Wes (Protein Simple), following the manufacturer’s
protocol. Primary antibodies used for this analysis were rabbit anti-p-ERK
(CST #4695S)78 and rabbit anti-ERK (CST #4370S)78.
Ras activation assay. Schwann cells were serum starved with DMEM supple-
mented with 0–1% FBS overnight before stimulation with complete media. Affinity
precipitation of Ras-GTP was performed using the active Ras pull-down and
detection Kit (Thermo Scientific), following the manufacturer’s protocol. Twenty
microliters of lysate was removed prior to affinity precipitation for quantification
of total Ras. A BCA assay was not performed due to low total protein. Relative
quantification of Ras-GTP to total Ras was done using the provided pan Ras
antibody on an automatic Simple Western apparatus, Wes (Protein Simple),
following the manufacturer’s protocol.
Immunofluorescence microscopy and staining. Cells were seeded on chamber
slides (Ibidi) coated with poly-L-lysine and laminin (see methods for Schwann
cell isolation) for 24–48 h, then fixed in 4% paraformaldehyde (EM Sciences) for
10 min at RT, permeabilized in 0.1% bovine serum albumin+ 0.2% Triton X-100
for 30 min at RT, then blocked in PBS+ 5% goat serum+ 5% glycerol+ 1% fish
gelatin (all from Sigma) for 1 h at RT. Cells were incubated overnight at 4 °C in
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blocking buffer+ rabbit anti-GFAP (Agilent Z0311), washed 3 × 5 min with PBS,
then stained with Phalloidin AF594 (Thermo A12381) and anti-rabbit IgG AF488
(Thermo A11008) for 1 h at RT in the dark. Slides were then washed as above and
mounted using Prolong Gold with DAPI (Thermo). DAPI, AlexaFluor488, and
AlexaFluor594 were imaged with a quad excitation filter (395/476/544/640),
dichroic LP beamsplitters (380/505/570), and emission filters (420LP/510-530/590-
650). Images were acquired on a Nikon TiE Inverted microscope equipped with an
Andor Zyla 5.5MP monochrome CMOS camera using a 20× objective and Nikon
Elements acquisition software. Image resolution is 2560 × 2160 pixels (216 nm/px).
Quantification of nuclei was performed using Fiji software79.
EM fixation and imaging. Porcine saphenous nerve and optic nerve were isolated
immediately upon euthanasia and incubated for 24–48 h at 4 °C in Karnovsky’s
fixation solution (4% paraformaldehyde and 3.2% glutaraldehyde in 0.1 M
phosphate buffer, pH 7.4–7.6), then transferred to sodium cacodylate buffer
(EM Sciences). Tissue was blocked, osmicated, dehydrated, and embedded in LX
112 (EMS) and processed for routine semi-thin and ultrathin sectioning. Sections
were stained in uranyl acetate and lead citrate and viewed on a Hitachi Model H-
7600 microscope.
Blood pressure measurements. Pigs were sedated with 5.5 mg kg−1 Telazol and
blood pressure measurements were taken by automated cuff (BP Accu-Gard, Vmed
Technology) and Doppler (ES-100VX MINIDOP, KOVEN Hadeco).
Statistics. All statistical analysis was done using a Student’s t-test to generate two-
tailed p values using GraphPad software or in R (version 3.43.1) R Studio PKNCA
package (version 0.8.1)77.
Data availability
The datasets generated during and/or analyzed during the current study are available
from the corresponding author on reasonable request. Animals and cell lines generated
in this publication are to be distributed by Recombinetics, a for-profit company.
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